US03589W1027

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 17:05 ET  | Source: Annexon Biosciences BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq:…

4 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025 22:55 ET  | Source: Annexon Biosciences BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”)…

6 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 07, 2025 16:30 ET  | Source: Annexon Biosciences New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions,…

10 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025 16:05 ET  | Source: Annexon Biosciences Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and…

11 months ago